Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - BioPharmX CorpFinancial_Report.xls
EX-31.1 - CERTIFICATIONS - BioPharmX Corpf10q0314ex31i_biopharm.htm
EX-32.1 - CERTIFICATIONS - BioPharmX Corpf10q0314ex32i_biopharm.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
   
ý                 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2014
 
or
   
o                 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                     to
    
Commission File No. 000-54871
 
BIOPHARMX CORPORATION
(Exact name of registrant as specified in its charter)
 
Nevada
 
59-3843182
(State or Other Jurisdiction of Incorporation or
Organization)
 
(I.R.S. Employer
Identification No.)
 
1098 Hamilton Court, Menlo Park, California
 
94025
(Address of principal executive offices)
 
(Zip Code)

Registrant's telephone number, including area code: 650-889-5020
 
Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
 
o Large accelerated filer
o Accelerated filer
o Non-accelerated filer
ý Smaller reporting company
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý
 
As of May 14, 2014, there were outstanding 9,025,000 shares of the registrant’s common stock, $.001 par value.

Documents incorporated by reference: None.
 


 
 

 
 
BIOPHARMX CORPORATION
 
Form 10-Q
 
Table of Contents
 
PART I – Financial Information
     
       
Item 1
Condensed Consolidated Financial Statements:
   
3
 
 
Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013 (unaudited)
   
3
 
 
Condensed Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2014 and 2013 (unaudited)
   
4
 
 
Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2014 and 2013 (unaudited)
   
5
 
 
Notes to Condensed Consolidated Financial Statements (unaudited)
   
6
 
Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
   
15
 
Item 3
Qualitative and Quantitative Disclosures About Market Risk
   
20
 
Item 4
Controls and Procedures
   
21
 
         
PART II – Other Information
       
         
Item 1
Legal Proceedings
   
22
 
Item 2
Unregistered Sales of Equity Securities and Use of Proceeds
   
22
 
Item 3
Defaults Upon Senior Securities
   
22
 
Item 4
Mine Safety Disclosures
   
22
 
Item 5
Other Information
   
22
 
Item 6
Exhibits
   
23
 
           
SIGNATURES
   
24
 
 
 
 

 
 
PART I
 
ITEM 1.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
BioPharmX Corporation
(a development stage enterprise)
Unaudited Condensed Consolidated Balance Sheets
as of March 31, 2014 and December 31, 2013
____________
   
March 31,
   
December 31,
 
 
2014
   
2013
 
Assets
           
Current assets:
           
Cash
 
$
57,000
   
$
3,000
 
Prepaid expenses and other current assets
   
55,000
     
36,000
 
Total current assets
   
112,000
     
39,000
 
                 
Property and equipment, net
   
41,000
     
32,000
 
Intangible assets
   
150,000
     
150,000
 
Other assets
   
150,000
     
150,000
 
                 
Total assets
 
$
453,000
   
$
371,000
 
                 
Liabilities and Stockholders' Deficit
               
                 
Current liabilities:
               
Accounts payable and accrued expenses
 
$
552,000
   
$
491,000
 
Deferred rent
   
62,000
     
65,000
 
Related party payables
   
188,000
     
125,000
 
Convertible notes, short-term
   
509,000
     
90,000
 
Total current liabilities
   
1,311,000
     
771,000
 
                 
Convertible notes payable
   
1,378,000
     
938,000
 
Other long-term liabilities
   
51,000
     
32,000
 
                 
Total liabilities
   
2,740,000
     
1,741,000
 
                 
Commitments and contingencies (Note 7)
               
                 
Stockholders' deficit:
               
Preferred stock, $0.001 par value; 10,000,000 shares authorized;
               
zero shares issued and outstanding
   
-
     
-
 
Common stock, $0.001 par value; 90,000,000 shares authorized;
               
9,025,000 and 7,025,000 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively
   
1,000
     
1,000
 
Additional paid-in capital
   
548,000
     
312,000
 
Deficit accumulated during the development stage
   
(2,836,000
)
 
(1,683,000
)
Total stockholders' deficit
   
(2,287,000
)
 
(1,370,000
)
                 
Total liabilities and stockholders' deficit
 
$
453,000
   
$
371,000
 
 
 
3

 
 
BioPharmX Corporation
(a development stage enterprise)
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
for the three months ended March 31, 2014 and 2013 and, cumulatively,
for the period from August 18, 2011 (date of inception) to March 31, 2014
____________
                 
   
Three months ended March 31,
   
Cumulative for the period from
 
August 18, 2011
(date of inception) to
March 31,
   
2014
   
2013
   
2014
 
                   
Operating expenses:
                 
Research and development
 
$
387,000
   
$
31,000
   
$
1,093,000
 
Sales and marketing
   
213,000
     
13,000
     
354,000
 
General and administrative
   
483,000
     
59,000
     
1,240,000
 
                         
Total operating expenses
   
1,083,000
     
103,000
     
2,687,000
 
                         
Loss from operations
   
(1,083,000
)
   
(103,000
)
   
(2,687,000
)
                         
Interest expense
   
(70,000
)
   
(6,000
)
   
(149,000
)
                         
Net and comprehensive loss
 
$
(1,153,000
)
 
$
(109,000
)
 
$
(2,836,000
)
                         
Basic and diluted net loss per share
 
$
(0.13
)
 
$
(0.02
)
       
                         
Shares used in computing basic and diluted net loss per share
   
9,025,000
     
7,383,000
         
 
 
4

 
 
BioPharmX Corporation
(a development stage enterprise)
Unaudited Condensed Consolidated Statements of Cash Flows
for the three months ended March 31, 2014 and 2013 and, cumulatively,
for the period from August 18, 2011 (date of inception) to March 31, 2014
____________
 
         
Cumulative for the period from
 
   
 
          August 18, 2011  
   
 
          (date of inception) to  
    Three months ended    
March 31,
 
   
2014
   
2013
   
2014
 
Cash flows from operating activities:
                 
Net loss
  $ (1,153,000 )   $ (109,000 )   $ (2,836,000 )
Adjustments to reconcile net loss to net cash used in operating activities:
                       
Stock-based compensation expense
    32,000       5,000       99,000  
Depreciation expense
    1,000       1,000       7,000  
Noncash interest expense
    70,000       6,000       149,000  
Changes in assets and liabilities:
                       
Prepaid expenses and other assets
    (19,000 )     -       (205,000 )
Accounts payable and accrued expenses
    50,000       64,000       513,000  
Related party payables
    63,000       -       188,000  
                         
Net cash used in operating activities
    (956,000 )     (33,000 )     (2,085,000 )
                         
Cash flows from investing activities:
                       
Purchases of property and equipment
    (10,000 )     -       (48,000 )
Purchase of intellectual property
    -       (50,000 )     (60,000 )
                         
Net cash used in investing activities
    (10,000 )     (50,000 )     (108,000 )
                         
Cash flows from financing activities:
                       
Proceeds from issuance of common stock
    -       -       -  
Repurchase of common stock
    -       -       -  
Proceeds from issuance of convertible notes payable
    1,020,000       50,000       2,250,000  
                         
Net cash provided by financing activities
    1,020,000       50,000       2,250,000  
                         
Net (decrease) increase in cash and cash equivalents
    54,000       (33,000 )     57,000  
Cash at beginning of period
    3,000       138,000       -  
Cash at end of Period
  $ 57,000     $ 105,000     $ 57,000  
 
 
5

 

BIOPHARMX CORPORATION
(a development stage enterprise)
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
1.
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
 
Description of Business

BioPharmX Corporation (“BioPharmX” or the “Company”) is a Silicon Valley-based company, incorporated in Nevada on August 30, 2010, that seeks to provide innovative products through unique, patented platform technologies for pharmaceutical and over-the-counter (“OTC”) applications in the fast growing dermatology and health and wellness markets.

The strategy of the Company begins with obtaining novel, patented, platform technologies through exclusive licensing, joint development or acquisition. BioPharmX then develops platform technologies that can be developed into product lines through specialized formulation and clinical protocol development with a bifurcated market penetration strategy, prescription for the high dose prescription version and OTC consumer for the low dose version. Identifying such technologies requires a strong knowledge of the markets served through technology assessment and evaluation of sell-side and buy-side opportunities through relationships with major pharmaceutical companies. BioPharmX’s products are formulated to address both market pathways to address unmet needs in well-defined, multi-billion dollar markets for licensing or direct commercialization for both pharmaceutical and OTC distribution and sales.
 
On January 23, 2014, the Company, BioPharmX Inc., a Delaware corporation (“BioPharmX, Inc.”) and stockholders of BioPharmX, Inc. who collectively own 100% of BioPharmX, Inc. (the “BioPharmX, Inc. Stockholders”) entered into and consummated transactions pursuant to a Share Exchange Agreement (the “Share Exchange Agreement,” such transaction referred to as the “Share Exchange Transaction”), whereby the Company issued to the BioPharmX, Inc. Stockholders an aggregate of 7,025,000 shares of its common stock, par value $0.001 (“Common Stock”), in exchange for 100% of the shares of BioPharmX, Inc. held by the BioPharmX, Inc. Stockholders. The shares of our Common Stock received by the BioPharmX, Inc. Stockholders in the Share Exchange Transaction constituted approximately 77.8% of our then issued and outstanding Common Stock giving effect to the issuance of shares pursuant to the Share Exchange Agreement.
  
As a result of the Share Exchange Transaction, BioPharmX, Inc. became a subsidiary of the Company. The acquisition was accounted for as a reverse merger and recapitalization effected by a share exchange. BioPharmX, Inc. is considered the acquirer for accounting and financial reporting purposes. The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized.

On March 3, 2014, we completed the name change of the Company from Thompson Designs, Inc. to BioPharmX Corporation.

Basis of Presentation and Principles of Consolidation

These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting and include the accounts of BioPharmX and its subsidiary. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, filed on March 31, 2014. The condensed consolidated balance sheet as of December 31, 2013, included herein, was derived from the audited consolidated financial statements as of that date.

 
6

 
 
The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of March 31, 2014 and December 31, 2013, the Company’s results of operations and its cash flows for each of the three months ended March 31, 2014 and 2013 and, cumulatively for the period from August 18, 2011 (date of inception) to March 31, 2014. The results for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014. All references to March 31, 2014 or to the three months ended March 31, 2014 and 2013 in the notes to the condensed consolidated financial statements are unaudited.
 
2.
GOING CONCERN CONSIDERATIONS AND MANAGEMENT’S PLAN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses and negative cash flows from operations since inception. The Company has not generated revenues and has funded its operating losses through the issuance of convertible notes payable. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the industry. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability. Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not contain any adjustments that might result from the outcome of this uncertainty.
 
As shown in the accompanying financial statements, the Company incurred a net loss of $1.2 million and $109,000 during the three months ended March 31, 2014 and 2013, respectively, and has an accumulated deficit of $2.8 million as of March 31, 2014. As of March 31, 2014, the Company had a working capital deficit of $1.2 million. As of December 31, 2013, the Company had a working capital deficit of $732,000. While management of the Company believes that it has a plan to fund on-going operations, there is no assurance that its plan will be successfully implemented.
 
Since 2012, the Company has obtained financing with convertible notes to invite early investors at a 20% discount to the share price in a future offering.  Additionally, during April 2014, the Company has issued Series A Preferred stock and warrants in consideration for $1.5 million (see details in Note. 13 -- “Subsequent Events”) and plans to close on additional funds as a result of this offering prior to the end of the second quarter. While the Company has been able to secure a number of investors, there is continued risk in the Company’s ability to attract additional development-stage investors. Without access to continued funds for working capital, the Company may not be able to execute its product strategy and pursue research and development activities on its novel platform technologies.
 
The discovery of key raw materials to formulate novel products depends on the Company’s ability to identify, negotiate and secure procurement of such materials. This also depends on the Company’s ability to establish comprehensive and long term vendor contracts and relationships.
 
The Company’s ability to compete and to achieve its product platform strategy depends on its ability to protect its proprietary discoveries and technologies. The Company currently relies on a combination of copyrights, trademarks, trade secret laws and confidentiality agreements to protect its intellectual property rights. The Company also relies upon unpatented know-how and continuing technological innovation.

The Company’s continued operations are dependent upon its ability to identify, recruit and retain adequate management personnel and contractors to perform certain jobs such as research and development, patent generation, regulatory affairs and general administrative functions. The Company requires highly trained professionals of varying levels and experience along with a flexible work force.

 
7

 
 
Research and development for novel prescription or OTC based products can be very extensive and lengthy in nature; along with the clinical trial process with the Food and Drug Administration which can require significant funding and time consuming patient studies. The competitive landscape could change significantly over the time period to complete targeted product development milestones. The current competition for BioPharmX’s products could also turn into strategic partners or potential acquirers in the future.

The significant risks and uncertainties described above could have a significant negative impact on the financial viability of BioPharmX and raise substantial doubt about the Company’s ability to continue as a going concern. Management is working on the Company’s business model to increase working capital by managing its cash flow, securing financing and working towards bringing its first product to market.
 
3.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
These financial statements and accompanying notes should be read in conjunction with the Company’s annual financial statements and notes thereto contained in the Annual Report on Form 10-K for the year ended December 31, 2013. There have been no significant changes in the Company’s significant accounting policies for the three months ended March 31, 2014, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2013.
 
4.
PROPERTY, PLANT AND EQUIPMENT
 
Property and equipment, consisted of the following:
 
   
March 31,
2014
   
December 31,
2013
 
             
Furniture and fixtures
 
$
11,000
   
$
11,000
 
Lab equipment
   
22,000
     
12,000
 
Computers and equipment
   
15,000
     
15,000
 
     
48,000
     
38,000
 
Less: accumulated depreciation
   
(7,000
)
   
(6,000
)
   
$
41,000
   
$
32,000
 
 
Depreciation expense for the three months ended March 31, 2014 and 2013 was $1,000 and $1,000.  Depreciation expense for the cumulative period from August 18, 2011 (date of inception) to March 31, 2014 totaled $7,000.
 
5.
RELATED PARTY PAYABLES

Since inception, the founding executives of the Company have made advances to cover short-term operating expenses. These advances are non-interest bearing. As of March 31, 2014 and December 31, 2013, related party payables were $188,000 and $125,000, respectively.
 
 
8

 
 
6.
LONG-TERM OBLIGATIONS
 
Financing Arrangements
 
The following table summarizes the carrying amount of our borrowings under various financing arrangements:
 
               
Interest
   
 
 
Type of Borrowing
 
Description
 
Issue Date
 
Due Date
 
Rate
   
Principal
 
Convertible notes as of December 31, 2013
         
 
    $ 1,230,000  
               
   
         
Convertible
 
Note
 
January 2014
 
January 2015
      6.00 %       350,000  
                             
Convertible
 
Note
 
January 2014
 
December 2016
      6.00 %       340,000  
                             
Convertible
 
Notes
 
January 2014
 
January 2017
      6.00 %       50,000  
                             
Convertible
 
Note
 
March 2014
 
January 2017
      6.00 %       30,000  
                             
Convertible
 
Note
 
March 2014
 
March 2017
      6.00 %       250,000  
                             
Convertible notes as of March 31, 2014             
                  $ 2,250,000  
                             
Less current portion
                    600,000  
                             
Total long-term debt, net
                  $ 1,650,000  
 
During the three months ended March 31, 2014, the Company issued convertible notes payable to twelve individuals in exchange for $1,020,000 in cash.  The Notes carry an interest rate of 6% per annum and mature between January 2015 and March 2017, with principal and interest payable at maturity.

The Notes automatically convert into preferred stock issued in a qualified financing at 80% of the price per share at which such preferred stock is issued in such an offering. Additionally, there is a special conversion that at maturity, unless the Company repays all outstanding principal and interest, the Notes shall be automatically converted into a number of shares of common stock of the Company at 80% of the then fair market value per share.

As a result of this beneficial conversion feature, the Company has recorded $204,000 and $246,000 as a debt discount during the three months ended March 31, 2014 and year ended December 31, 2013. The debt discount is being amortized to interest expense over the term of the Notes using the effective interest rate method. The amortization expense related to the debt discount was $43,000 and $3,000 for the three months ended March 31, 2014 and 2013, respectively and $87,000 for the cumulative period from August 18, 2011 (date of inception) to March 31, 2014. The note holders as a group also have the right to purchase up to an aggregate of $1.5 million in shares in the event of a subsequent offer of equity securities, see Note 13.
 
 
9

 
 
7.
COMMITMENTS AND CONTINGENCIES
 
Lease Arrangements

On August 23, 2013, the Company signed a lease for 10,800 square feet of office and laboratory space in Menlo Park, California. The term of the lease is 39 months from the lease commencement date of September 1, 2013. Future minimum commitments under this lease are as follows:
 
Nine month remaining of 2014
 
$
210,000
 
2015
   
288,000
 
2016
   
271,000
 
Total
 
$
769,000
 
 
Legal Proceedings

We are not currently a party to any legal proceedings. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
 
8.
STOCKHOLDERS' EQUITY
 
Common Stock
 
As described in Note 1, on January 23, 2014, the Company issued 7,025,000 shares of its common stock to BioPharmX, Inc. stockholders.  As a result, the Company has 9,025,000 shares of common stock currently issued and outstanding.
 
Series A Preferred Stock
 
On March 14, 2014, we entered into a Subscription Agreement for a private placement of shares of our Series A Preferred Stock (“Series A”) and warrants with an accredited investor, whereby we will sell an aggregate of 540,977 shares of our Series A preferred stock, par value $0.001 per share at a per share price of $1.85 for gross proceeds of $1,000,000 and to issue to the investors for no additional consideration warrants (the “Warrants”) to purchase 270,489 shares of the Company’s common stock in the aggregate at an exercise price of $3.70 per share upon the closing of Series A.
 
On March 14, 2014, the Company, the majority shareholders of the Company and the subscriber who is the party to the Subscription Agreement entered into an Investor Rights Agreements, whereby the subscriber was granted certain rights including: (i) right to receive copies of quarterly and annual reports of the Company, (ii) right of inspection of the Company’s properties and records, (iii) right of participation in future securities offerings, (iv) tag-along rights in connection with sales of the Company’s stock by a major shareholder, and (v) board of directors representation rights for the subscribers who purchased at least 500,000 shares of Series A and hold at least 30% of such shares (the “Qualified Subscribers”). The Company made certain covenants under the agreement including: (i) uplisting to NYSE or NASDAQ within three years from the issuance shares of Series A, and (ii) increase of the board of directors to five members including one member to be appointed by the Qualified Subscribers.

On March 20, 2014, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designations, Preferences, Rights and Limitations of Series A (the “Series A Certificate”).  Pursuant to the Series A Certificate, there are 3.3 million shares of Series A authorized.

As discussed in Note 13, the first closing of the sale of Series A occurred on April 11, 2014, at which time the Series A was issued and the proceeds were released to the Company.
 
Equity Incentive Plan

On August 18, 2011, BioPharmX, Inc. adopted the 2011 Equity Incentive Plan (the “BioPharmX, Inc. Plan”) which permits BioPharmX, Inc. to grant stock options to directors, officers or employees of the Company or others to purchase shares of common stock of BioPharmX, Inc. through awards of incentive and nonqualified stock options (“Options”), stock (“Restricted Stock” or “Unrestricted Stock”) and stock appreciation rights (“SARs”). On January 23, 2014, immediately after the closing of the Share Exchange Transaction which resulted in a reverse acquisition of the Company by BioPharmX, Inc., the Company adopted the 2014 Equity Incentive Plan (the “2014 Plan”), options issued under the BioPharmX, Inc. Plan were cancelled, and options under the 2014 Plan were issued to replace all cancelled BioPharmX, Inc., options.
 
The Company currently has time-based options outstanding. The time-based options generally vest in two to four years and expire ten years from the date of grant. Total number of shares reserved and available for grant and issuance pursuant to this Plan is 3,600,000. Shares issued under the Plan will be drawn from authorized and unissued shares or shares now held or subsequently acquired by the Company. At March 31, 2014, there were 994,000 shares available for grant under the Plan. There was no incremental value recorded in relation to this exchange.
 
There was no stock option activity for the three month period ended March 31, 2014.
 
 
10

 
 
9.
STOCK-BASED COMPENSATION
 
The following table summarizes the stock-based compensation expenses included in our Unaudited Condensed Consolidated Statement of Operations and Comprehensive Loss:
 
               
Cumulative for the period from
August 18 2011
 
   
For the three months ended
   
(date of inception) to
 
   
of March 31
   
March 31,
 
   
2014
   
2013
   
2014
 
Research and development
  $ 23,000     $ 1,000     $ 58,000  
                         
Sales and marketing
    4,000       1,000       11,000  
                         
General and administrative
    5,000       3,000       30,000  
                         
Stock-based compensation expense
  $ 32,000     $ 5,000     $ 99,000  
 
The Company estimates the fair value of time-based stock options, if any, granted using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Time-based and performance-based options, if any, typically have a ten-year life from date of grant and vesting periods of two to four years.
 
Valuation Assumptions

The fair value of stock-based awards to employees is calculated through the use of the Black-Scholes option pricing model, even though such model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from the Company’s stock option awards. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values.
 
Expected Term

The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data.

Expected Volatility

The Company uses the historical volatility of the price of the common shares of selected public companies in the biotechnology sector.

Expected Dividend

The Company has never paid dividends on its common shares and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.
 
 
11

 

Risk-Free Interest Rate

The Company bases the risk-free interest rate used in the Black-Scholes option pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model.
 
We used the following assumptions to calculate the estimated fair value of the awards:
 
  For the three months ended March 31,
 
  2013  
Expected volatility
   
82.1
%
Expected term in years
   
5.52 - 6.08
 
Risk-free interest rate
   
0.67% - 0.89
%
Expected dividend yield
   
%
 
 
12

 
 
10.
FAIR VALUE MEASUREMENTS
 
The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value.
 
 
Level 1 - Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
 
 
Level 2 - Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
 
 
Level 3 - Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity.
 
As of March 31, 2014 and December 31, 2013, the Company held no assets or liabilities with instrument valuations measured on a recurring basis.
 
11.
INCOME TAXES
 
No federal income taxes were provided in the three months ended March 31, 2014 and 2013 or for the cumulative period from August 18, 2011 (date of inception) to March 31, 2014 due to the Company’s net losses. State minimum income and franchise taxes are included in general and administrative expenses and were immaterial for the periods presented.  The Company evaluates its ability to recover deferred tax assets, in full or in part, by considering all available positive and negative evidence, including past operating results and our forecast of future taxable income on a jurisdictional basis. The Company bases its estimate of current and deferred taxes on the tax laws and rates that are currently in effect in the appropriate jurisdiction. Changes in laws or rates may affect the tax provision as well as the amount of deferred tax assets or liabilities.
 
Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carry-forwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carry-forwards could be limited.

As of March 31, 2014 and December 31, 2013, the Company did not have any material unrecognized tax benefits. The 2013 and 2012 tax years remain open for examination by the federal and state authorities.
 
 
13

 
 
12.
NET LOSS PER SHARE

Basic net loss per share is computed by dividing income attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities by adding other common stock equivalents, including common stock options, warrants, and convertible notes, in the weighted average number of common shares outstanding for a period, if dilutive. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. For the three months ended March 31, 2014 and 2013, 3.7 million and 1.5 million potentially dilutive securities, respectively, were excluded from the computation of diluted loss per share because their effect on net loss per share was anti-dilutive. As a result of the net loss for each of the three months ended March 31, 2014 and 2013 there is no dilutive impact to the net loss per share calculation for the periods.
 
13.
SUBSEQUENT EVENTS
 
The Company entered into Subscription Agreements (the “Subscription Agreements”) for a private placement (the “Private Placement”) of shares of our Series A, par value $0.001 per share, and warrants (the “Warrants”) with two accredited investors (the “Investors”) during the first quarter of 2014 and April 1, 2014, respectively, whereby we sold an aggregate of 810,811 shares of Series A at a per share price of $1.85 for gross proceeds of $1,500,000 and issued to the investors for no additional consideration the Warrants to purchase in the aggregate 405,406 shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $3.70 per share. The closing of the sale of the Series A and the Warrants under the Subscription Agreements occurred on April 11, 2014 (the “Private Placement”) , at which time the Series A was issued and the proceeds were released to the Company 

In connection with the Subscription Agreements, the Company, the majority shareholders of the Company and the Investors entered into an Investor Rights Agreement (the “Investor Rights Agreement”) with the Investors on March 14, 2014 and April 1, 2014, respectively, whereby the Investors were granted certain rights including: (i) right to receive copies of quarterly and annual reports of the Company, (ii) right of inspection of the Company’s properties and records, (iii) right of participation in future securities offerings, (iv) tag-along rights in connection with sales of the Company’s stock by a major shareholder, and (v) board of directors representation rights for the subscribers who purchased at least 500,000 shares of Series A and hold at least 30% of such shares (the “Qualified Subscribers”). The Company made certain covenants under the agreement including: (i) uplisting to NYSE or NASDAQ within three years from the issuance shares of Series A, and (ii) increase of the board of directors to five members including one member to be appointed by the Qualified Subscribers.

As a result of the closing of the Private Placement, the 6% secured convertible notes in the aggregate principal amount of $2.25 million previously issued were automatically converted into 1,520,280 shares of common stock of the Company (the “Conversion Shares”).

 
14

 
 
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are subject to risks and uncertainties. One can identify these forward-looking statements by their use of words such as “expect,” “plan,” “will,” “may,” “anticipate,” “believe,” “estimate,” “should,” “intend,” “forecast,” “project” the negative or plural of these words, and other comparable terminology. One can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results and product and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors described in the Company’s filings with the SEC, especially the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q. In various filings the Company has identified important factors that could cause actual results to differ from expected or historic results. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete list of all potential risks or uncertainties.
 
The following discussion is presented on a consolidated basis, and analyzes our financial condition and results of operations for the three months ended March 31, 2014 and 2013. Unless the context indicates or suggests otherwise, reference to “we”, “our”, “us” and the “Company” in this section refers to the consolidated operations of BioPharmX Corporation, as defined in Note 1 —Description of Business and Basis of Presentation to the financial statements.
 
The following Management's Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, is intended to help the reader understand our results of operations and financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes to the financial statements and other disclosures included in this Quarterly Report on Form 10-Q. Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.
 
Overview

BioPharmX Corporation, “BioPharmX, “we,” “us” or the” Company” was incorporated in Nevada on August 30, 2010 under the name “Thompson Designs, Inc.”  The business plan of the Company was originally to design and build custom signs for residential and commercial properties. Immediately after the completion of the Share Exchange Transaction (see details below), the Company discontinued its custom signs business and changed its business plan to development of novel delivery mechanisms and routes of administration for known drugs and tissues.

BioPharmX, Inc. incorporated in Delaware on August 18, 2011, and headquartered in Menlo Park, California, is a wholly-owned subsidiary of the Company. It is a research-based biopharmaceutical company that seeks to provide innovative products through unique, proprietary platform technologies for pharmaceutical and over-the-counter, or OTC, applications in the fast growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat).
 
We are primarily a research and development, or R&D, company focusing on the development of novel delivery mechanisms and novel routes of administration for known drugs and tissues.  We have expertise in formulation development, intellectual property generation, clinical trial execution, and regulatory strategy definition.  Our business model is to outsource much of its manufacturing and commercialization activities in order to maintain its focus on technology sourcing, acquisitions, and partner development to create new products to address unmet needs in well-defined, multi-billion dollar markets
 
 
15

 

Share Exchange Agreement
 
On January 23, 2014, the Company, BioPharmX, Inc. and stockholders of BioPharmX, Inc., who collectively own 100% of BioPharmX, Inc. (the “BioPharmX, Inc. Stockholders”) entered into and consummated transactions pursuant to a Share Exchange Agreement (the “Share Exchange Agreement,” such transaction referred to as the “Share Exchange Transaction”), whereby the Company issued to the BioPharmX, Inc. Stockholders an aggregate of 7,025,000 shares of its common stock, par value $0.001 (“Common Stock”), in exchange for 100% of the shares of BioPharmX, Inc. held by the BioPharmX, Inc. Stockholders. The shares of our Common Stock received by the BioPharmX, Inc. Stockholders in the Share Exchange Transaction constituted approximately 77.8% of our then issued and outstanding Common Stock giving effect to the issuance of shares pursuant to the Share Exchange Agreement.
  
Series A Preferred Stock
 
The Company entered into Subscription Agreements (the “Subscription Agreements”) for a private placement (the “Private Placement”) of shares of our Series A, par value $0.001 per share, and warrants (the “Warrants”) with two accredited investors (the “Investors”) on March 14, 2014 and April 1, 2014, respectively, whereby we sold an aggregate of 810,811 shares of Series A at a per share price of $1.85 for gross proceeds of $1,500,000 and issued to the investors for no additional consideration the Warrants to purchase in the aggregate 405,406 shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $3.70 per share. The closing of the sale of the Series A and the Warrants under the Subscription Agreements occurred on April 11, 2014 (the “Private Placement”) , at which time the Series A was issued and the proceeds were released to the Company 
 
In connection with the Subscription Agreements, the Company, the majority shareholders of the Company and the Investors entered into an Investor Rights Agreement (the “Investor Rights Agreement”) with the Investors on March 14, 2014 and April 1, 2014, respectively, whereby the Investors were granted certain rights including: (i) right to receive copies of quarterly and annual reports of the Company, (ii) right of inspection of the Company’s properties and records, (iii) right of participation in future securities offerings, (iv) tag-along rights in connection with sales of the Company’s stock by a major shareholder, and (v) board of directors representation rights for the subscribers who purchased at least 500,000 shares of Series A and hold at least 30% of such shares (the “Qualified Subscribers”). The Company made certain covenants under the agreement including: (i) uplisting to NYSE or NASDAQ within three years from the issuance shares of Series A, and (ii) increase of the board of directors to five members including one member to be appointed by the Qualified Subscribers.
 
As a result of the closing of the Private Placement, the 6% secured convertible notes in the aggregate principal amount of $2.25 million previously issued were automatically converted into 1,520,280 shares of common stock of the Company (the “Conversion Shares”).
 
Critical Accounting Policies
 
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States, or GAAP. GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.  
 
 
16

 
 
Our significant accounting policies are summarized in Note 1 of our audited financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2013. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.
  
We believe the following critical accounting policies and procedures, among others, affect our more significant judgments and estimates used in the preparation of our financial statements:
 
Results of Operations

Three months ended March 31, 2014 and 2013

Revenue

From August 18, 2011 (date of inception) through March 31, 2014, we have not had any revenues.  We are in the research and development stage, but we project our molecular iodine dietary supplement product will be released in late 2014.
 
Research and Development Expenses

Research and development expenses for the three months ended March 31, 2014 and 2013 were $387,000 and $31,000, respectively.  The increase from year-to-year is due to the increase in consultants during 2013. Research and development during the first quarter of 2014 used a combination of four full-time employees and consultants and several part-time consultants. We employed only one full-time consultant during the first quarter of 2013. Research and development expenses for the three months ended March 31, 2014, consisted primarily of compensation expense in the amount of $312,000, laboratory supplies of $20,000 and $55,000 of facilities and related overhead.   Research and development expenses for the period from August 18, 2011 (date of inception) through March 31, 2014 consisted of $860,000 of compensation and benefits, $80,000 in laboratory supplies and $116,000 of overhead. We plan to convert some of our current consultants to employees later in 2014.

Sales and Marketing Expenses

Sales and marketing expenses for the three months ended March 31, 2014 and 2013 were $213,000 and $13,000, respectively.  The increase from year-to-year is because the Company used only a consultant for developing their website and logo.  Sales and marketing expenses for the three months ended March 31, 2014, consisted primarily of compensation in the amount of $60,000, the cost of developing marketing strategy and material in the amount of $142,000 and facilities and related overhead of $11,000.  Sales and marketing expenses for the period from August 18, 2011 (date of inception) through March 31, 2014 consisted primarily of $142,000 for compensation and benefits and $178,000 for the development of marketing strategy and materials and $21,000 of facilities and related overhead.  We currently have no employees in sales and marketing and plan to continue to use outside consultants for this work, some of whom we may hire later in 2014.
 
General and Administrative Expenses
 
General and administrative expenses for the three months ended March 31, 2014 and 2013 were $483,000 and $59,000, respectively.  The increase from year-to-year is primarily due to the legal fees and costs related to the company’s reverse acquisition.  General and administrative expenses for the three months ended March 31, 2014 consisted primarily of compensation and benefits in the amount of $264,000, professional fees totaling $97,000 to our legal counsel and auditors, travel expense of $19,000, as well as $103,000 of corporate and other general and administrative expenses. General and administrative expenses for the period from August 18, 2011 (date of inception) through March 31, 2014 consisted primarily of $588,000 in compensation and benefits, $359,000 for professional fees, $84,000 in travel expense, as well as $234,000 of corporate and other general and administrative expenses.
 
 
17

 
 
Loss from Operations
 
Loss from operations for the three months ended March 31, 2014 and 2013 was $1.1 million and $103,000, respectively.  The increase in the loss from year-to-year is due to the Company ramping up research and development, legal and audit costs related to the reverse acquisition we completed in the first quarter of 2014  and other operations. Loss from operations for period from August 18, 2011 (date of inception) through March 31, 2014, was $2.7 million.
 
Net Loss
 
Net loss for the three months ended March 31, 2014 and 2013 was $1.2 million and $109,000, respectively. Net loss for the period from August 18, 2011 (date of inception) through March 31, 2014, was $2.8 million.
 
Inflation did not have a material impact on the Company’s operations for either of the periods. Other than the foregoing, management knows of no trends, demands, or uncertainties that are reasonably likely to have a material impact on the Company’s results of operations. 

Capital Resources and Liquidity
 
A summary of the sources and uses of cash and cash equivalents is as follows:
 
   
For the Three Months Ended
March 31,
   
Cumulative for the period from August 14, 2011 (date of inception) to March 31,
 
   
2014
   
2013
   
2014
 
Net cash used in operating activities
 
$
(956,000
)
 
$
(33,000
 
$
(2,085,000
)
Net cash used in investing activities
   
(10,000
)
   
  (50,000
)
   
(108,000
)
Net cash used in financing activities
   
1,020,000
     
  50,000
     
2,250,000
 
                         
Net increase (decrease) in cash and cash equivalents
 
$
54,000
   
$
(33,000
)
 
$
57,000
 

At March 31, 2014, we had a working capital deficit of $1,199,000.
 
 
18

 

Net cash used for operating activities for the three months ended March 31, 2014 was $1.0 million.  Cash used in operating activities was primarily due to net loss for the three months ended March 31, 2014 of $1.2 million which was partially offset by changes in operating assets and liabilities of $94,000, non-cash interest expense of $70,000 and stock-based compensation of $32,000. Cash used in investing activities was primarily for acquisition of fixed assets.

Net cash used for operating activities for the three months ended March 31, 2013 was $33,000.  Cash used in operating activities was primarily due to net loss for the three months ended March 31, 2013 of $109,000 which was offset by $64,000 increase in accounts payable and accrued expenses, non-cash interest expense of $6,000 and stock-based compensation of $5,000. Cash used in investing activities was primarily for acquisition of intellectual property.

Net cash obtained through all financing activities for the three months ended March 31, 2014 and 2013 was $1.0 million and $50,000, respectively, in proceeds from issuing convertible notes payable.
 
In the first quarter of 2014, BioPharmX, Inc. issued to an accredited investor 6% secured convertible notes in the aggregate principal amount of $1.02 million. The notes are secured by all the assets of BioPharmX, Inc. pursuant to the Security Agreement dated January 3, 2014, by and between BioPharmX, Inc. and the collateral agent, and rank senior to any other indebtedness of BioPharmX, Inc. The notes are automatically convertible into the shares of common stock of the Company, contingent on the completion of the reverse acquisition of the Company by BioPharmX, Inc. and closing of a financing in the amount of at least $500,000 at a conversion price per share equal to 80% of the per share offering price of such financing. The investor has the right to receive at the closing of the reverse acquisition warrants to purchase shares of common stock of the Company equal to 100% of the shares of common stock underlying the respective notes.

Between September 2012 and March 2014, the Company issued 6% unsecured convertible notes to investors in the aggregate principal amount of $2.3 million. These notes have a maturity dates from one to three years from the date of issuance, with principal and interest payable at maturity. The notes are automatically convertible into the securities of the Company sold in an offering that takes place after the completion of the reverse acquisition of the Company by BioPharmX, Inc., contingent on the completion of the reverse acquisition and closing of such financing at a conversion price per share equal to 80% of the per share offering price of such financing.
 
On April 11, 2014, we sold an aggregate of 810,811 shares of our Series A Preferred Stock at a per share price of $1.85 for gross proceeds of $1.5 million and issued to the investors for no additional consideration warrants (the “Warrants”) to purchase 405,406 shares of the Company’s common stock in the aggregate at an exercise price of $3.70 per share.
 
Going Concern

As reflected in the accompanying financial statements, the Company has a net loss of $1.2 million and $109,000, respectively, for the three months ended March 31, 2014 and 2013, respectively and a deficit accumulated during the development stage of $2.8 million as of March 31, 2014.  The net cash used in operations for the three months ended March 31, 2014 and 2013 was $956,000 and $33,000, respectively.

The ability of the Company to continue its operations is dependent on Management's plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.  The Company may need to incur additional liabilities with certain related parties to sustain the Company’s existence.
  
 
19

 
 
The Company may require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives.  The Company believes its current available cash along with anticipated revenues may be insufficient to meet its cash needs for the near future if it does not receive the anticipated additional funding. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. In that event, the Company would be required to change itgrowth strategy and seek funding on that basis, if at all.
 
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
 
In response to the above, management will:
 
 
seek additional third party debt and/or equity financing;

 
continue with the implementation of the business plan;

 
seek to generate revenue through commercialization of the technology.

To date, all of our funding has been generated from private investments. During the next twelve months, we anticipate raising funding to continue expansion; however, as of this writing, we only have sufficient funds to proceed with basic company operations only. We do not have sufficient funds to fully implement our business plan until such time that we are able to raise additional funding, to which there is no guarantee. If we do not obtain the funds necessary for us to continue our business activities we may need to curtail or cease our operations until such time as we have sufficient funds.
 
On January 23, 2014, the Company, BioPharmX, Inc. and stockholders of BioPharmX, Inc., who collectively own 100% of BioPharmX, Inc. (the “BioPharmX, Inc. Stockholders”) entered into and consummated transactions pursuant to the Share Exchange Agreement, whereby the Company issued to the BioPharmX, Inc. Stockholders an aggregate of 7,025,000 shares of its common stock, par value $0.001 (“Common Stock”), in exchange for 100% of the shares of BioPharmX, Inc. held by the BioPharmX, Inc. Stockholders. The shares of our Common Stock received by the BioPharmX, Inc. Stockholders in the Share Exchange Transaction constituted approximately 77.8% of our issued and outstanding Common Stock giving effect to the issuance of shares pursuant to the Share Exchange Agreement.
  
As a result of the Share Exchange Transaction, BioPharmX, Inc. became a subsidiary of the Company. The acquisition was accounted for as a reverse merger and recapitalization effected by a share exchange. BioPharmX, Inc. is considered the acquirer for accounting and financial reporting purposes. The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized.
 
ITEM 3.
QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK
 
Pursuant to Item 305(e) of Regulation S-K the Company, as a smaller reporting company, is not required to provide the information required by this item.
 
 
20

 
 
ITEM 4.
CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures.
 
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
 
Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this quarterly report.
 
Changes in Internal Controls over Financial Reporting

No change in our system of internal control over financial reporting occurred during the three months ended March 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 
21

 
 
PART II

OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS
 
We are not currently a party to any legal proceedings. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
 
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
None.
 
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4.
MINE SAFETY DISCLOSURES
 
None.
 
ITEM 5.
OTHER INFORMATION
 
None.
 
 
22

 

ITEM 6.
EXHIBITS
 
Exhibit No.
 
Description
 
31.1
 
Certifications by the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1
Certifications by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS
XBRL Instance Document.
   
101.SCH
XBRL Schema Document
   
101.CAL
XBRL Calculation Linkbase Document
   
101.DEF
XBRL Definition Linkbase Document
   
101.LAB
XBRL Label Linkbase Document
   
101.PRE
XBRL Presentation Linkbase Document
 

* Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 27, 2014.
 
 
23

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioPharmX Corporation
 
       
Date: May 15, 2014
By:
/s/ James Pekarsky
 
   
Name: James Pekarsky
 
   
Title: Chief Executive Officer,
Chief Financial Officer and Director
(Principal Executive Officer, Principal Financial Officer and
Principal Accounting Officer)
 
 
 
24